Post-marketing Surveillance of Spesolimab I.V. Infusion in improvement of Generalized Pustular Psoriasis (GPP) with acute symptoms in Japan (PMS for GPP with acute symptoms)

25/11/2022
16/11/2026
EU PAS number:
EUPAS49953
Study
Finalised
Study identification

EU PAS number

EUPAS49953

Study ID

49954

Official title and acronym

Post-marketing Surveillance of Spesolimab I.V. Infusion in improvement of Generalized Pustular Psoriasis (GPP) with acute symptoms in Japan (PMS for GPP with acute symptoms)

DARWIN EU® study

No

Study countries

Japan

Study description

The primary outcome is the incidence of investigator/BI-defined drug reactions (including safety concerns: Serious infections, Serious hypersensitivity).

Study status

Finalised
Research institutions and networks
No information provided.

Contact details

Yukako Ogi

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

Study start date

Actual:

Date of final study report

Actual:
Sources of funding

More details on funding

Nippon Boehringer Ingelheim Co., Ltd.
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Non-EU RMP only